The role of cytokines in acute graft-versus-host disease

Cytokines, Cellular and Molecular Therapy

Volumn 3, Issue 4, 1997, Pages 257-265

  Hill, Geoffrey R ^a   Krenger, Werner ^a,b   Ferrara, James L M ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bone marrow transplantation; Cytokines; Graft versus host disease; IFN ; IL 1 ; IL 2; LPS; TNF

Indexed keywords

ALLOANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGY; INFLAMMATION; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; CYTOKINES; GRAFT VS HOST DISEASE; HUMANS;

EID: 0030688877     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Storb R, Prevention of graft-versus-host disease after bone marrow transplantation. Transplant Proc (1995) 27: 2653-6.
2. Ringden O, Deeg HJ, Clinical spectrum of graft-versus-host disease. In: Graft-vs-Host Disease, 2nd edn (ed JLM Ferrara, HJ Deeg, SJ Burakoff) 525-59. Marcel Dekker, New York, 1997.
3. Hakim FT, Mackall CL, The immune system: effector and target of graft-versus-host disease. In: Graft-vs-Host Disease, 2nd edn (ed JLM Ferrara, HJ Deeg, SJ Burakoff) 257-89. Marcel Dekker, New York, 1997.
4. Martin PJ, Kernan NA, T-cell depletion for GVHD prevention in humans. In: Graft-vs-Host Disease, 2nd edn (ed JLM Ferrara, HJ Deeg, SJ Burakoff) 615-38. Marcel Dekker, New York, 1997.
5. Holler E, Ferrara JLM, Antagonists of inflammatory cytokines: prophylactic and therapeutic applications. In: Graft-vs-Host Disease, 2nd edn (ed JLM Ferrara, HJ Deeg, SJ Burakofi) 667-92. Marcel Dekker, New York, 1997.
6. Deeg HJ, Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. Bone Marrow Transplant (1994) 14: S56-S60.
7. Xun CQ, Thompson JS, Jennings CD et al, Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood (1994) 83: 2360-7.
8. Remberger M, Ringden O, Markling L, TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant (1995) 15: 99-104.
9. Eissner G, Kohlhuber F, Grell M et al, Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood (1995) 86: 4184-93.
10. Behrends U, Peter RU, Hintermeier-Knabe R et al, Ionizing radiation induces human intercellular adhesion molecule-1 in vitro. J Invest Dermatol (1994) 103: 726-30.
11. Lichtman A, Krenger W, Ferrara JLM, Cytokine networks. In: Graft-vs-Host Disease, 2nd edn (ed JLM Ferrara, HJ Deeg, SJ Burakoff) 179-218. Marcel Dekker, New York, 1997.
12. Hill GR, Crawford JM, Cooke KJ et al, Total body irradiation effects on acute graft versus host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood (1997) 90: 3204-13.
13. Holler E, Kolb HJ, Moller A, et al, Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood (1990) 75: 1011-16.
14. Holler E, Kolb HJ, Mittermueller J et al, Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F). Blood (1995) 86: 890-9.
15. Korngold R, Sprent J, T cell subsets in graft-vs.-host disease. In: Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment (ed SJ Burakoff, HJ Deeg, J Ferrara, K Atkinson) 31-50. Marcel Dekker, New York, 1990.
16. Korngold R, Sprent J, Features of T cells causing H-2 restricted lethal graft-vs-host disease across minor histocompatibility barriers. J Exp Med (1982) 155: 872-3.
17. Mosmann TR, Cherwinski H, Bond MW et al, Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 136: 2348-57.
18. Seder RA, The functional role of CD8+ T helper type 2 cells. J Exp Med (1995) 181: 5-7.
19. Nestel FP, Price KS, Seemayer TA, Lapp WS, Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med (1992) 175: 405-13.
20. Via CS, Finkelman FD, Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol (1993) 5: 565-72.
21. Theobald M, Nierle T, Bunjes D et al, Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med (1992) 327: 1613-17.
22. Schwarer AP, Jiang YZ, Brookes PA et al, Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet (1993) 341: 203-5.
23. Gribben JG, Guinan EC, Boussiotis VA et al, Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: a method to ameliorate graft-versus-host disease and extend the donor pool. Blood (1996) 87: 4887-93.
24. Miyamoto T, Akashi K, Hayashi S et al, Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant (1996) 17: 185-90.
25. Ringden O, Cyclosporine in allogeneic bone marrow transplantation. Transplantation (1986) 42: 445-52.
26. Anasetti C, Hansen JA, Waldmann TA et al, Treatment of acute graft versus host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood (1994) 84: 1320-7.
27. Cahn JY, Bordigoni P, Tiberghien P et al, Treatment of acute graft versus host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. Transplantation (1995) 60: 939-42.
28. Anasetti C, Martin PJ, Storb R et al, Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant (1991) 7: 375-81.
29. Biaise D, Marananinchi D, Mawas C et al, Prevention of acute graft versus host disease by monoclonal antibody to interleukin 2 receptor. Lancet (1989) i: 1333-4.
30. Biaise D, Olive D, Michallet M et al, Impairment of leukaemia-free survival by addition of interleukin-2 receptor antibody to standard-graft-versus host prophylaxis. Lancet (1995) 345: 1144-66.
31. Belanger C, Esperou-Bourdeau H, Bordigoni P et al, Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant (1993) 11: 293-7.
32. Massumoto C, Benyunes MC, Sale G, Close stimulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancies. Bone Marrow Transplant (1996) 17: 351-6.
33. Weiss L, Lubin I, Factorowich I et al, Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. J Immunol (1994) 153: 2562-7.
34. Soiffer RJ, Murray C, Cochran K et al, Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted bone marrow transplantation. Blood (1992) 79: 517-26.
35. Robinson N, Sanders JE, Benyunes MC et al, Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood (1996) 87: 1249-54.
36. Sykes M, Romick ML, Hoyles KA, Sachs DH, In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med (1990) 171: 645-58.
37. Szebeni J, Wang MG, Pearson DA et al, IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host disease. Transplantation (1994) 58: 1385-93.
38. Wang MG, Szebeni J, Pearson DA et al, Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells. Transplantation (1995) 60: 481-90.
39. Sykes M, Abraham VS, Harty MW, Pearson DA, IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol (1993) 150: 197-205.
40. Sykes M, Szot GL, Nguyen PL, Pearson DA, Interleukin-12 inhibits murine graft-versus-host disease. Blood (1995) 86: 2429-38.
41. Troutt AB, Maraskovsky E, Rogers LA et al, Quantitative analysis of lymphokine expression in vivo and in vitro. Immunol Cell Biol (1992) 70: 51-7.
42. Allen RD, Staley TA, Sidman CL, Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunology (1993) 23: 333-7.
43. Garside P, Reid S, Steel M, Mowat AM, Differential cytokine production associated with distinct phases of murine graft-versus-host reaction. Immunol (1994) 82: 211-14.
44. Ferrara JLM, Cooke KR, Pan L, Krenger W, The immunopathophysiology of acute graft-versus-host disease. Stem Cells (1996) 14: 473-89.
45. Mowat A, Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunol (1989) 68: 18-24.
46. Dickinson AM, Sviland L, Dunn J et al, Demonstration of direct involvement of cytokines in graft-versus-host reactions using an in vitro skin explant model. Bone Marrow Transplant (1991) 7: 209-16.
47. Wall DA, Sheehan KC, The role of tumor necrosis factor-alpha and interferon gamma in graft-versus-host disease and related immunodeficiency. Transplantation (1994) 57: 273-9.
48. Huchet R, Bruley-Rosset M, Mathiot C et al, Involvement of IFN-gamma and transforming growth factor-beta in graft-vs-host reaction-associated immunosuppression. J Immunol (1993) 150: 2517-24.
49. Krenger W, Falzarano G, Delmonte J et al, Interferon-γ suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood (1996) 88: 1113-21.
50. Rus V, Svetic A, Nguyen P et al, Kinetics of Th1 and Th2 cytokine production during the early course of acute and chronic murine graft-versus-host disease. J Immunol (1995) 155: 2396-406.
51. Brok HPM, Heidt PJ, van der Meide PH et al, Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Immunol (1993) 151: 6451-9.
52. Smith SR, Terminelli C, Pennline K et al, Inhibitory effects of recombinant human interleukin 10 on disease manifestations in a P→F1 model of acute graft versus host disease. Transplantation (1995) 59: 890-6.
53. Carayon P, Bouaboula M, Loubet JF et al, The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-gamma and GM-CSF mRNA expression. Int F Immunopharmacol (1995) 17: 753-61.
54. Krenger W, Snyder KM, Byon CH et al, Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol (1995) 155: 585-93.
55. Fowler DH, Kurasawa K, Husebekk A et al, Cells of the Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. J Immunol (1994) 152: 1004-11.
56. Imamura M, Hashino S, Kobayashi H et al, Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant (1994) 13: 745-51.
57. Niederwieser D, Herold M, Woloszczuk W et al, Endogenous IFN-gamma during human bone marrow transplantation. Transplantation (1990) 50: 620-5.
58. Kennedy MJ, Vogelsang GB, Jones RJ et al, Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol (1994) 12: 249-57.
59. Dickinson, AM, Sviland L, Hamilton PJ et al, Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow trans-plant recipients. Bone Marrow Transplant (1994) 13: 65-70.
60. Tanaka J, Imamura M, Kasai M et al, Cytokine gene expression in the mixed lymphocyte culture in allogenic bone marrow transplants as a predictive method for transplantation-related complications. Br F Haematol (1994) 87: 415-18.
61. Roncarolo MG, Bigler M, Ciuti E et al, Immune responses by cord blood cells. Blood Cells (1994) 20: 573-85.
62. Kurtzberg J, Laughlin M, Graham ML, Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med (1996) 335: 157-66.
63. Heinzel FP, Sadick MD, Holaday BJ et al, Reciprocal expression of interferon-gamma or interleukin-4 during the resolution or progression of murine leishmaniasis. J Exp Med (1989) 169: 59-72.
64. Romagnani S, Lymphokine production by human T cells in disease states. Annu Rev Immunol (1994) 12: 227-57.
65. Sher A, Gazzinelli RT, Oswals IP et al, Role of T cell-derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev (1992) 127: 183-204.
66. Doutrelepont JM, Moser M, Leo O et al, HyperIgE in stimulatory graft-versus-host disease: role of interleukin-4. Clin Exp Immunol (1991) 83: 133-6.
67. DeWit D, Van Mechelen M, Zanin C et al, Preferential activation of Th2 cells in chronic graft-versus-host disease. J Immunol (1993) 150: 361-6.
68. Garlisi CG, Pennline KJ, Smith SR et al, Cytokine gene expression in mice undergoing chronic graft-versus-host disease. Mol Immunol (1993) 30: 669-77.
69. Via CS, Rus V, Gately MK, Finkelman FD, IL-12 stimulates the development of acute graft-versus-host disease in mice that would normally develop chronic, autoimmune graft-versus-host disease. J Immunol (1994) 153: 4040-7.
70. Fowler DH, Gress RE, Graft-versus-host disease as a Th1-type process: regulation by donor cells of Th2 cytokine phenotype. In: Graft-vs-Host Disease, 2nd edn (ed JLM Ferrara, HJ Deeg, SJ Burakoff) 479-500. Marcel Dekker, New York, 1997.
71. Krenger W, Ferrara JLM, Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res (1996) 15: 50-73.
72. Strom TB, Roy-Chaudhury P, Manfro R et al, The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol (1996) 8: 688-93.
73. Piccotti JR, Chan SY, Goodman RE, IL-12 antagonism induces T helper 2 responses yet exacerbates cardiac allograft rejection. J Immunol (1996) 157: 1951-7.
74. Krenger W, Cooke KR, Sonis ST et al, Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation (1996) 62: 1278-85.
75. Krenger W, Snyder K, Smith S, Ferrara JLM, Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation (1994) 58: 1251-7.
76. Blazar BR, Taylor PA, Smith S, Vallera DA, Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood (1995) 85: 842-51.
77. Atkinson K, Matias C, Guiffre A et al, In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood (1991) 77: 1376-82.
78. Bensinger WI, Clift RA, Anasetti C et al, Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells (1996) 14: 90-105.
79. Pan L, Delmonte J, Jalonen CK, Ferrara JLM, Pretreatment of donors with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type 2 cytokine production and reduces severity of experimental graft versus host disease. Blood (1995) 86: 4422-9.
80. Braun YM, Lowin B, French L et al, Cytotoxic T cells deficient in both functional Fas ligand and perform show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med (1996) 183: 657-61.
81. Baker MB, Altman NH, Podack ER, Levy RB, The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med (1996) 183: 2645-56.
82. Ferrara J, Guillen FJ, Sleckman B et al, Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol (1986) 86: 371-5.
83. Hoffman RA, Langrehr JM, Simmons RL, Induction of nitric oxide synthesis during the immune response. In: Chimerism and Tolerance (ed ST Ildstad) 79-84. RG Landes, 1995.
84. Graubert TA, Russell JH, Ley T, The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood (1996) 87: 1232-7.
85. Piguet PF, Tumor necrosis factor and graft-versus-host disease. In: Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment (ed SJ Burakoff, HJ Deeg, JLM Ferrara, K Atkinson) 255-76. Marcel Dekker, New York, 1990.
86. McCarthy PL, Abhyankar S, Neben S et al, Inhibition of interleukin-1 by interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood (1991) 78: 1915-18.
87. Abhyankar S, Gilliland DG, Ferrara JLM, Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft-versus-host disease to minor histocompatibility antigens. Transplantation (1993) 56: 1518-23.
88. Falzarano G, Krenger W, Snyder KM et al, Suppression of B cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease. Blood (1996) 87: 2853-60.
89. Moller B, Ellerman-Eriksen S, Storgaard M et al, Soluble tumor necrosis factor (TNF) receptors conserve TNF bioactivity in meningitis patient spinal fluid. J Infect Dis (1996) 174: 557-63.
90. Steinshamn S, Bemelmans MH, Buurman WA, Waage A, Granulocytopenia reduces release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine (1995) 7: 50-60.